Healthpeak Properties heads into its August 4 earnings with an unusual split: analysts are still lifting targets, but short sellers have spent the past month quietly rebuilding positions — and the two signals are now pointing in opposite directions.
The short interest story is the week's most notable development, and it marks a clear change from the picture described in last week's note. Short interest has climbed roughly 36% over the past month, reaching nearly 4% of the free float — up from around 2.9% in early June. The move accelerated in the first two weeks of July, with shares short jumping from 23.3 million to 27.4 million in a single week. That is a meaningful build by any measure. Borrow costs remain low — the cost to borrow runs at about 0.55%, up roughly 25% on the week but still firmly in the low-cost tier — and availability is exceptionally loose at over 4,500% of short interest, meaning there are roughly 46 shares available to borrow for every one currently shorted. The lending market creates no friction for new bears. The ORTEX short score has drifted higher this week, reaching 36.8, its highest point in this run — not an extreme reading in absolute terms, but a directional move worth noting.
Options traders are not joining the bears. The put/call ratio at 0.42 runs slightly below its 20-day average of 0.44 — a fractionally more bullish lean, nothing dramatic — and sits far below the 52-week high of 1.59. There is no sign of defensive hedging building in the options market ahead of earnings, which stands in contrast to the short interest rebuild.
On the Street, the target-raising cycle that characterised last week's note has continued. Wells Fargo lifted its Equal-Weight target to $22 from $20 on July 15 — today's session — bringing the consensus mean target to around $21.92, almost exactly at the current price of $21.66. Every firm that has touched the name in recent weeks has raised its number, with Mizuho at $24 and BMO Capital at $24 representing the bull camp, while Wells Fargo, UBS at $21.50, and Morgan Stanley at $22 cluster around or below current levels with neutral-equivalent ratings. The 14 hold-rated analysts in the consensus reflect a Street that has warmed to the stock but stopped short of outright conviction. EPS surprise factors rank in the 99th percentile — Healthpeak has consistently beaten estimates — but forward EPS momentum over 90 days ranks in just the 4th percentile, and the bear case centres on lab-tenant credit risk and soft leasing in the life science portfolio weighing on the 2026-27 growth outlook.
Peer price action this week adds mild context. Closest correlated peer ARE fell 3.9% over the week, a steeper drop than DOC's 1.2% decline. HR and LTC held up better, each gaining over 1%. The mixed peer tape does not point to a sector-wide rotation — DOC's short build looks more name-specific than macro-driven.
Earnings history adds a wild card. The last two quarterly prints produced next-day moves of roughly 19-20% to the upside, with five-day gains of 18-21%. The print before that delivered a 2.7% next-day gain but a 23% five-day move. These are unusually large reactions for a mid-cap healthcare REIT, which makes the August 4 release a higher-stakes event than the muted options positioning currently implies — and gives the short rebuild a clearer potential catalyst to test against.
What to watch next: whether short interest continues to add through the final weeks before the August 4 print, and whether the options market begins to price in some of the historical earnings volatility that has repeatedly caught the stock in large post-print moves.
See the live data behind this article on ORTEX.
Open DOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
